Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

547
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
547

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What Makes a Great Manuscript?

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Noninvasive Predictive Model for Rapid Hemodynamic Optimization During Mechanical Circulatory Support.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Circulatory arrest time above 30 min have significantly detrimental effects on the outcomes of type a aortic dissection repair.

Journal of cardiothoracic surgery·2026
Same author

Temporary circulatory support for cardiogenic shock: technology overview and limitations.

Expert review of medical devices·2026
Same author

Computational hemodynamic assessment of axillary and femoral artery perfusion for extracorporeal left ventricular assist device.

Frontiers in cardiovascular medicine·2025
Same author

ASAIO 2025 Annual Conference Summary.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2025

Related Experiment Video

Updated: Mar 27, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.2K

Future Prospects for the Total Artificial Heart.

Gengo Sunagawa1, David J Horvath1, Jamshid H Karimov1

  • 1a Department of Biomedical Engineering , Lerner Research Institute, Cleveland Clinic , Cleveland , OH , USA.

Expert Review of Medical Devices
|January 7, 2016
PubMed
Summary
This summary is machine-generated.

Total artificial hearts (TAHs) are crucial for biventricular failure but current models have limitations. Future TAHs should incorporate continuous-flow technology for improved patient outcomes.

Keywords:
Artificial heartContinuous flowHeart failureHeart transplantationPulsatile flowVentricular assist device

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.4K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K

Related Experiment Videos

Last Updated: Mar 27, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.2K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.4K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

10.1K

Area of Science:

  • Cardiovascular Surgery
  • Biomedical Engineering
  • Medical Devices

Background:

  • Total artificial hearts (TAHs) are a last resort for biventricular heart failure when left ventricular assist devices (LVADs) are insufficient.
  • Current clinical TAHs are pulsatile, posing challenges like large size, uncertain durability, complex anticoagulation, and significant complications.
  • The limitations of pulsatile TAHs include noise and cumbersome external equipment.

Purpose of the Study:

  • To review the current status of total artificial heart technology.
  • To outline essential requirements for future TAH designs.

Main Methods:

  • Literature review of current and developing TAH technologies.
  • Analysis of limitations associated with existing pulsatile TAHs.
  • Identification of key features for next-generation TAHs.

Main Results:

  • Pulsatile TAHs face significant design and clinical hurdles.
  • Continuous-flow technology, successful in LVADs, is driving TAH innovation.
  • Novel continuous-flow TAHs are primarily in preclinical or developmental phases.

Conclusions:

  • Advancements in TAH technology are critical for patients with end-stage biventricular failure.
  • Future TAHs should leverage continuous-flow principles to overcome current limitations.
  • Defining requirements for future TAHs is essential for guiding research and development.